MaxCyte, Inc. Purchase of Common Stock (2493T)
November 23 2021 - 2:32AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 2493T
MaxCyte, Inc.
23 November 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Purchase of Common Stock - PDMR dealing
Gaithersburg, Maryland, November 23, 2021 - MaxCyte, Inc.,
(NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial
cell-engineering company focused on providing enabling platform
technologies to advance innovative cell-based research as well as
next-generation cell therapeutic discovery, development and
commercialization, announces that Richard Douglas, Non-Executive
Chairman of MaxCyte, Inc. purchased 20,000 shares on the open
market of common stock of the Company ("Common Stock"). The 20,000
shares of Common Stock were purchased at an average price of
$11.124 per share ("Purchase"). The Purchase represents
approximately 13% of Richard Douglas' aggregate equity and option
holdings in the Company's stock capital.
Following the Purchase, Richard Douglas holds 20,000 shares of
Common Stock representing 0.02% of the issued stock capital of the
Company. Following the Purchase, Richard Douglas holds a further
131,600 options over Common Stock.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 100,838,137 and the number of restricted
shares of Common Stock trading under the symbol 'MXCL' is
330,000.
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: three instruments, the ATx(TM), STx(TM) and
GTx(TM); a portfolio of proprietary related processing assemblies
or disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and/or persons closely
associated with them:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name a) Richard Douglas
------------------------------------------------------------ -----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------------------------
a) Non-Executive Chairman
a) Position/status
------------------------------------------------------------ -----------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------------ -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------------------------
a) Name MaxCyte, Inc.
------------------------------------------------------------ -----------------------------------------
b) LEI 54930053YHXULRFCU991
------------------------------------------------------------ -----------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument $0.01 ordinary shares
Identification code
US57777K1060
------------------------------------------------------------ -----------------------------------------
b) Nature of the transaction Purchase of Common Stock
------------------------------------------------------------ -----------------------------------------
c) Price(s) and volume(s) Price(s) per Ordinary Volume(s)
Share
a) $11.005 a) 100
b) $11.01 b) 697
c) $11.03 c) 360
d) $11.04 d) 512
e) $11.05 e) 128
f) $11.06 f) 64
g) $11.08 g) 200
h) $11.09 h) 528
i) $11.1 i) 300
j) $11.11 j) 300
k) $11.12 k) 2,400
l) $11.13 l) 3,200
m) $11.139 m) 1,400
n) $11.14 n) 7,000
o) $11.15 o) 2,300
p) $11.159 p) 511
---------------------- ---------------
------------------------------------------------------------ -----------------------------------------
d) Aggregated information:
* Aggregated volume: 20,000
N/A
-- Price:
------------------------------------------------------------ -----------------------------------------
e) Date of the transaction 22 November 2021
------------------------------------------------------------ -----------------------------------------
f) Place of the transaction Nasdaq Stock Market
------------------------------------------------------------ -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPGUWGUPGUMW
(END) Dow Jones Newswires
November 23, 2021 02:32 ET (07:32 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
